{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:53:05Z","timestamp":1791273185530,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lungcan.2026.109538","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:59:02Z","timestamp":1784530742000},"page":"109538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative efficacy of taletrectinib versus first-generation TKIs in TKI-na\u00efve ROS1+\u00a0non-small cell lung cancer: A matching-adjusted indirect comparison"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5308-615X","authenticated-orcid":false,"given":"Misako","family":"Nagasaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3296-423X","authenticated-orcid":false,"given":"Maurice","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila","family":"Bazhenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109538_b0005","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109538_b0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","article-title":"ROS1-dependent cancers\u2014biology, diagnostics and therapeutics","volume":"18","author":"Drilon","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109538_b0015","unstructured":"US Food and Drug Administration, Xalkori (crizotinib) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217581s000lbl.pdf, 2023 (accessed March 31, 2026)."},{"key":"10.1016\/j.lungcan.2026.109538_b0020","unstructured":"US Food and Drug Administration, Rozlytrek (entrectinib) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/212725s011lbl.pdf, 2024 (accessed March 31, 2026)."},{"key":"10.1016\/j.lungcan.2026.109538_b0025","unstructured":"US Food and Drug Administration, Augtyro (repotrectinib) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218213s001lbl.pdf, 2024 (accessed March 31, 2026)."},{"key":"10.1016\/j.lungcan.2026.109538_b0030","unstructured":"Nuvation Bio Inc., IBTROZI (taletrectinib) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219713s000lbl.pdf, 2025 (accessed March 31, 2026)."},{"key":"10.1016\/j.lungcan.2026.109538_b0035","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109538_b0040","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.20.03025","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion\u2013positive non\u2013small-cell lung cancer","volume":"39","author":"Dziadziuszko","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109538_b0045","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/oncolo\/oyae205","article-title":"Advances and future directions in ROS1 fusion-positive lung cancer","volume":"29","author":"Boulanger","year":"2024","journal-title":"Oncologist."},{"key":"10.1016\/j.lungcan.2026.109538_b0050","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3390\/pharmaceutics13091446","article-title":"Brain metastasis treatment: the place of tyrosine kinase inhibitors and how to facilitate their diffusion across the blood\u2013brain barrier","volume":"13","author":"Angeli","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.lungcan.2026.109538_b0055","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The incidence of brain metastases in stage IV ROS1-rearranged non\u2013small cell lung cancer and rate of central nervous system progression on crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109538_b0060","article-title":"Characteristics of short-term survivors with ALK or ROS1 altered metastatic non-small cell lung cancer (mNSCLC)","author":"Liu","year":"2025","journal-title":"JTO. Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2026.109538_b0065","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109538_b0070","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1038\/s41467-019-11496-z","article-title":"The new-generation selective ROS1\/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models","volume":"10","author":"Katayama","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2026.109538_b0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/fon-2022-1059","article-title":"TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors","volume":"19","author":"Nagasaka","year":"2023","journal-title":"Future. Oncol."},{"key":"10.1016\/j.lungcan.2026.109538_b0080","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1200\/JCO-25-00275","article-title":"Taletrectinib in ROS1+ non-small cell lung cancer: TRUST","volume":"43","author":"Perol","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109538_b0085","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V.5.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed April 30, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"key":"10.1016\/j.lungcan.2026.109538_b0090","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion\u2013positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2026.109538_b0095","doi-asserted-by":"crossref","unstructured":"Y. Fan, A. Drilon, C.H. Chiu, H.H.F. Loong, S. Siena, M. Krzakowski, et al., Brief report: updated efficacy and safety data from an intergrated analysis of entrectinib in locally advanced\/metastatic ROS1 fusion-positive non-small-cell lung cancer, Clin. Lung. Cancer. 25 (2024) e81\u2013e86 e4. https:\/\/doi.org\/10.1016\/j.cllc.2023.12.001.","DOI":"10.1016\/j.cllc.2023.12.001"},{"key":"10.1016\/j.lungcan.2026.109538_b0100","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2217\/cer-2020-0063","article-title":"Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer","volume":"9","author":"Chu","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.lungcan.2026.109538_b0105","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3390\/cancers17050748","article-title":"Population-adjusted indirect treatment comparisons of repotrectinib among patients with ROS1+ NSCLC","volume":"17","author":"Wolf","year":"2025","journal-title":"Cancers."},{"key":"10.1016\/j.lungcan.2026.109538_b0110","unstructured":"D. Phillippo, T. Ades, S. Dias, S. Palmer, K.R. Abrams, N. Welton, NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. https:\/\/research-information.bris.ac.uk\/en\/publications\/nice-dsu-technical-support-document-18-methods-for-population-adj\/, 2016 (accessed March 31, 2026)."},{"key":"10.1016\/j.lungcan.2026.109538_b0115","doi-asserted-by":"crossref","first-page":"CT300","DOI":"10.1158\/1538-7445.AM2026-CT300","article-title":"CT300: Taletrectinib in tyrosine kinase inhibitor (TKI)-na\u00efve patients with ROS1+ non-small cell lung cancer (NSCLC): updated data from TRUST-I and TRUST-II","volume":"86","author":"Bazhenova","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109538_b0120","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Central Nervous System Cancers V.1.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed April 30, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:26:11Z","timestamp":1791271571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"alternative-id":["S0169500226005994"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109538","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of taletrectinib versus first-generation TKIs in TKI-na\u00efve ROS1+\u00a0non-small cell lung cancer: A matching-adjusted indirect comparison","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109538"}}